SynBioBeta Speaker
Ebihara Takashi
GeneFrontier
COO
The COO of GeneFrontier Corporation (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. Earned a Ph.D. in cell-free protein synthesis from Tokyo Institute of Technology in 2000, and played ...
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Ebihara
This Year
•
-
Tools & Tech
25 Years of the PURE System: Rebuilding Cell-Free Protein Synthesis for the Future
The PURE system, invented 25 years ago, established a fully reconstituted approach to cell-free protein synthesis. What began as a system to better understand translation has evolved into a versatile platform for engineering biology. This talk highlights how PURE-derived platforms such as PUREfrex® enable rapid prototyping, high-throughput screening, and AI/ML-driven optimization, accelerating synthetic biology and next-generation biologics development.
Get a Ticket
•
-
Tools & Tech
25 Years of the PURE System: Rebuilding Cell-Free Protein Synthesis for the Future
The PURE system, invented 25 years ago, established a fully reconstituted approach to cell-free protein synthesis. What began as a system to better understand translation has evolved into a versatile platform for engineering biology. This talk highlights how PURE-derived platforms such as PUREfrex® enable rapid prototyping, high-throughput screening, and AI/ML-driven optimization, accelerating synthetic biology and next-generation biologics development.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
